CN113891725A - 包含血管紧张素ii的固态组合物及其制备方法、使用方法、用途 - Google Patents

包含血管紧张素ii的固态组合物及其制备方法、使用方法、用途 Download PDF

Info

Publication number
CN113891725A
CN113891725A CN202080037975.5A CN202080037975A CN113891725A CN 113891725 A CN113891725 A CN 113891725A CN 202080037975 A CN202080037975 A CN 202080037975A CN 113891725 A CN113891725 A CN 113891725A
Authority
CN
China
Prior art keywords
composition
angiotensin
mass ratio
supplemental
range
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080037975.5A
Other languages
English (en)
Other versions
CN113891725B (zh
Inventor
王立坤
张凤娥
顾国祥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Haiwei Pharmaceutical Technology Co ltd
Original Assignee
Nanjing Haiwei Pharmaceutical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Haiwei Pharmaceutical Technology Co ltd filed Critical Nanjing Haiwei Pharmaceutical Technology Co ltd
Publication of CN113891725A publication Critical patent/CN113891725A/zh
Application granted granted Critical
Publication of CN113891725B publication Critical patent/CN113891725B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

一种包含血管紧张素II的固态组合物及其制备方法、使用方法和用途。所述组合物包括：血管紧张素II和辅助添加剂，其中，辅助添加剂包括磺丁基β环糊精或海藻糖；血管紧张素II与辅助添加剂的质量比在0.012:10‑10:10范围内。所述固态组合物稳定性高，可以在常温下保存两年以上。

Description

PCT国内申请，说明书已公开。

Claims (11)

  1. PCT国内申请，权利要求书已公开。
CN202080037975.5A 2019-10-31 2020-10-30 包含血管紧张素ii的固态组合物及其制备方法、使用方法、用途 Active CN113891725B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019110548674 2019-10-31
CN201911054867.4A CN112807281A (zh) 2019-10-31 2019-10-31 包含血管紧张素ii的稳定组合物及其制备方法、使用方法
PCT/CN2020/125530 WO2021083372A1 (zh) 2019-10-31 2020-10-30 包含血管紧张素ii的固态组合物及其制备方法、使用方法、用途

Publications (2)

Publication Number Publication Date
CN113891725A true CN113891725A (zh) 2022-01-04
CN113891725B CN113891725B (zh) 2022-11-29

Family

ID=75688253

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201911054867.4A Withdrawn CN112807281A (zh) 2019-10-31 2019-10-31 包含血管紧张素ii的稳定组合物及其制备方法、使用方法
CN202080037975.5A Active CN113891725B (zh) 2019-10-31 2020-10-30 包含血管紧张素ii的固态组合物及其制备方法、使用方法、用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201911054867.4A Withdrawn CN112807281A (zh) 2019-10-31 2019-10-31 包含血管紧张素ii的稳定组合物及其制备方法、使用方法

Country Status (3)

Country Link
US (1) US20210128531A1 (zh)
CN (2) CN112807281A (zh)
WO (1) WO2021083372A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112807281A (zh) * 2019-10-31 2021-05-18 南京海维医药科技有限公司 包含血管紧张素ii的稳定组合物及其制备方法、使用方法

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919443A (en) * 1992-12-18 1999-07-06 Boehringer Manheim Gmbh Stable lyophilized pharmaceutical preparations of G-CSF
WO2007008496A1 (en) * 2005-07-06 2007-01-18 Kanisa Pharmaceuticals, Inc. Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
CN101039660A (zh) * 2004-08-12 2007-09-19 先灵公司 稳定的聚乙二醇化干扰素制剂
CN101045063A (zh) * 2006-03-28 2007-10-03 广州朗圣药业有限公司 注射用克拉霉素水溶性制剂
WO2009056651A1 (en) * 2007-11-02 2009-05-07 Cytos Biotechnology Ag Angiotensin-carrier formulation
CN101969929A (zh) * 2008-01-15 2011-02-09 雅培股份有限两合公司 粉末状蛋白质组合物及其制备方法
CN101990548A (zh) * 2008-02-18 2011-03-23 玛丽王后·威斯特费尔学院 6313/G2(抗血管紧张肽Ⅱ 1型受体)单克隆抗体可变区的合成的scFv类似物
CN103720667A (zh) * 2014-01-09 2014-04-16 中国药科大学 Ap-25多肽冻干粉针制剂及其制备方法和用途
US20170087215A1 (en) * 2015-09-25 2017-03-30 Xeris Pharmaceuticals, Inc. Methods for Producing Stable Therapeutic Formulations in Aprotic Polar Solvents
CN108653217A (zh) * 2018-07-04 2018-10-16 四川农业大学 一种妥曲珠利包合物冻干粉及其制备方法
CN111346220A (zh) * 2018-12-24 2020-06-30 山东先声生物制药有限公司 一种聚乙二醇修饰的血管内皮抑制素制剂组合物
CN112807281A (zh) * 2019-10-31 2021-05-18 南京海维医药科技有限公司 包含血管紧张素ii的稳定组合物及其制备方法、使用方法

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919443A (en) * 1992-12-18 1999-07-06 Boehringer Manheim Gmbh Stable lyophilized pharmaceutical preparations of G-CSF
CN101039660A (zh) * 2004-08-12 2007-09-19 先灵公司 稳定的聚乙二醇化干扰素制剂
WO2007008496A1 (en) * 2005-07-06 2007-01-18 Kanisa Pharmaceuticals, Inc. Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
CN101045063A (zh) * 2006-03-28 2007-10-03 广州朗圣药业有限公司 注射用克拉霉素水溶性制剂
WO2009056651A1 (en) * 2007-11-02 2009-05-07 Cytos Biotechnology Ag Angiotensin-carrier formulation
CN101969929A (zh) * 2008-01-15 2011-02-09 雅培股份有限两合公司 粉末状蛋白质组合物及其制备方法
CN101990548A (zh) * 2008-02-18 2011-03-23 玛丽王后·威斯特费尔学院 6313/G2(抗血管紧张肽Ⅱ 1型受体)单克隆抗体可变区的合成的scFv类似物
CN103720667A (zh) * 2014-01-09 2014-04-16 中国药科大学 Ap-25多肽冻干粉针制剂及其制备方法和用途
US20170087215A1 (en) * 2015-09-25 2017-03-30 Xeris Pharmaceuticals, Inc. Methods for Producing Stable Therapeutic Formulations in Aprotic Polar Solvents
CN108653217A (zh) * 2018-07-04 2018-10-16 四川农业大学 一种妥曲珠利包合物冻干粉及其制备方法
CN111346220A (zh) * 2018-12-24 2020-06-30 山东先声生物制药有限公司 一种聚乙二醇修饰的血管内皮抑制素制剂组合物
CN112807281A (zh) * 2019-10-31 2021-05-18 南京海维医药科技有限公司 包含血管紧张素ii的稳定组合物及其制备方法、使用方法

Also Published As

Publication number Publication date
US20210128531A1 (en) 2021-05-06
WO2021083372A1 (zh) 2021-05-06
CN112807281A (zh) 2021-05-18
CN113891725B (zh) 2022-11-29

Similar Documents

Publication Publication Date Title
EP3102184B1 (en) Stable peptide formulations and methods for preparation
CN100546574C (zh) 注射用扑热息痛液态制剂
TW201141506A (en) Daptomycin compositions and related methods
CZ299464B6 (cs) Implantovatelný systém pro dodávání léciva, zpusob jeho prípravy a použití formulace peptidové slouceniny
US9168238B2 (en) Levothyroxine formulations
US10869848B2 (en) Carmustine pharmaceutical composition
AU2017364135B2 (en) Pharmaceutical parenteral formulation containing carglumic acid
CN113891725B (zh) 包含血管紧张素ii的固态组合物及其制备方法、使用方法、用途
EP3372242A1 (en) Liquid pharmaceutical composition
EA036982B1 (ru) Способ получения лиофилизированной фармацевтической композиции, содержащей митомицин с
JPH0314520A (ja) インターロイキン―１組成物
KR20160048227A (ko) 고나도트로핀을 위한 제제
Liu et al. Thermal stability of exenatide encapsulated in stratified dissolving microneedles during storage
US20220233634A1 (en) Formulations of terlipressin
EP3607969A1 (en) Infliximab composition containing histidine buffer system
KR20240047452A (ko) 동결건조 제형 용액과 동결건조 제형, 및 이의 방법과 용도
CN103239416B (zh) 一种单硝酸异山梨酯的注射用组合物及其制备方法
CN104173278A (zh) 一种基于Brij97液晶的皮下注射给药系统及其制备方法
WO2022116134A1 (zh) 磷苯妥英钠固体组合物、冻干方法、及其用途
JP2007506683A (ja) ヒト成長ホルモン剤およびその調整方法と使用方法
CA3194375A1 (en) Vacuum drying method for botulinum toxin
TW202027729A (zh) 免疫蛋白酶體抑制劑調配物
CN115624527A (zh) 一种尼可地尔冻干粉针剂及其制备方法和用途
JP2022549201A (ja) 皮下注射可能なインスリンおよびグルカゴン製剤ならびに投与方法
CA2904670A1 (en) Voriconazole formulations

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant